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DBC1 (deleted in breast cancer 1), also known as
CCAR2 or KIAA1967, is an important negative regu-
lator of SIRT1 and cellular stress response. Although
the Dbc1 gene localizes at a region that is homozy-
gously deleted in breast cancer, its role in tumorigen-
esis remains unclear. It has been suggested to be
either a tumor suppressor or an oncogene. There-
fore, the function of DBC1 in cancer needs to be
further explored. Here, we report thatDbc1 knockout
mice are tumor prone, suggesting that DBC1 func-
tions as a tumor suppressor in vivo. Our data suggest
that the increased tumor incidence inDbc1 knockout
mice is independent of Sirt1. Instead, we found that
DBC1 loss results in less p53 protein in vitro and
in vivo. DBC1 directly binds p53 and stabilizes it
through competition with MDM2. These studies
reveal that DBC1 plays an important role in tumor
suppression through p53 regulation.INTRODUCTION
p53 is a pivotal tumor suppressor and one of the most mutated
genes in human cancer, with p53 mutations observed in over
half of all human cancers (Brady and Attardi, 2010; Vousden
and Prives, 2009). p53 regulates multiple cellular functions,
including apoptosis, cell cycle arrest, cell metabolism, and
senescence. One of the major regulatory mechanisms of p53 is
its ubiquitination by a ubiquitin E3 ligase MDM2 (murine double
minute 2), which leads to p53 degradation under normal condi-
tions (Haupt et al., 1997). Under stress conditions, such as
DNA damage, viral infection, and oncogene activation, p53 is
quickly accumulated, resulting in its activation. Several mecha-
nisms are responsible for p53 induction, including MDM2 in-
activation, interrupted interaction between p53 and MDM2,
and activation of ubiquitin proteases (Dai and Gu, 2010).
The Dbc1 gene was initially discovered as a gene deleted in
human chromosome 8p21 in breast cancer (Hamaguchi et al.,
2002). DBC1 is composed of a leucine zipper motif at the amino1324 Cell Reports 10, 1324–1334, March 3, 2015 ª2015 The Authorsterminus, coiled coil domain at the carboxy terminus, a nuclear
localization signal, an EF hand domain, and a Nudix domain
(Anantharaman and Aravind, 2008; Kim et al., 2008). DBC1 is
processed into C-terminal p120 and p66 fragments, which re-
locate from nucleus to mitochondria and enhance apoptotic
signaling with tumor necrosis factor-a (TNFa) treatment in
HeLa cells (Sundararajan et al., 2005). Several studies also
suggest that DBC1 regulates hormone receptor activity. For
instance, DBC1 activates retinoic acid receptor a and androgen
receptor and represses transcription activity of estrogen recep-
tor b (Fu et al., 2009; Garapaty et al., 2009; Koyama et al., 2010).
Furthermore, we and others have found that DBC1 negatively
regulates SIRT1 activity through binding to its active site (Kim
et al., 2008; Zhao et al., 2008). DNA damage and oxidative stress
increase the DBC1-SIRT1 interaction, whereas PKA and AMPK
induce dissociation of SIRT1 from DBC1 (Yuan et al., 2012; Nin
et al., 2012). DBC1 also binds to methyltransferase SUV39H1
and inhibits cellular H3K9 methylation (Li et al., 2009).
The role of DBC1 in tumorigenesis is more puzzling. Dbc1 is
deleted in several types of cancer and has been suggested to
suppress tumor development (Hamaguchi et al., 2002; Kim
et al., 2009; Di Marcotullio et al., 2011). DBC1 is also associated
with good outcome in gastric cancer (Noguchi et al., 2014), but
other studies have shown that DBC1 is overexpressed in breast
cancer, gastric cancer, and other tumor types and is correlated
with poor prognosis (Cha et al., 2009; Hiraike et al., 2010;
Kang et al., 2012; Zhang et al., 2014). Downregulation of DBC1
inhibits the proliferation and invasive potential of gastric cancer
cells (Bae et al., 2014). Because of these conflicting findings,
DBC1 function in tumorigenesis remains unclear.
Here we show that p53 level is decreased in DBC1-deficient
cells and tissues. DBC1 binds to the N terminus andDNA binding
domain of p53, competing with MDM2 and stabilizing p53.
Depletion of Dbc1 promotes tumorigenesis in mice.
RESULTS
DBC1 Loss Promotes Tumorigenesis
To test that DBC1 is a bona fide tumor suppressor in vivo, we
generated Dbc1 knockout (KO) mice. Dbc1+/+, Dbc1+/, and
Dbc1/ mice were monitored for 24 months. Dbc1 KO mice
were born in expected Mendelian ratios (Table S1), but
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Figure 1. DBC1 Deficiency Promotes Tumorigenesis In Vivo
(A) Kaplan-Meier disease-free survival curves of Dbc1+/+ (n = 80), Dbc1+/ (n = 80), and Dbc1/ (n = 62) mice for 24 months, p < 0.0001.
(B) Representative images of H&E staining of tumors from DBC1/ mice.
(C) Tumor incidence in Dbc1+/+ (n = 44), Dbc1+/ (n = 42), and Dbc1/ (n = 59) mice.
See also Figure S1.compared with Dbc1+/+ mice, the disease-free survival of
Dbc1+/ and Dbc1/ mice was dramatically decreased (Fig-
ure 1A). Dbc1+/ and Dbc1/ mice developed more tumors
than Dbc1+/+ mice, including lymphomas, liver tumors, lung tu-
mors, and teratomas (Figures 1B, 1C, and S1). Further analysis
of these tumors showed that lymphomas and liver tumors are
the primary tumors. In Dbc1/ mice, liver tumors and lym-
phomas took up to16.95% and 16.95%, respectively. Lung tu-p53
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Cemors and teratomas took 8.47% and 3.39% (Table S2). These
results indicate that DBC1 is a tumor suppressor.
Stabilization of p53 by DBC1
In our investigation of DBC1 tumor suppressor function in vitro
using Dbc1 KO cells, we unexpectedly found that the p53 level
decreased in Dbc1 KO cells under unstressed condition (Fig-
ure 2A). In addition, p53 induction following DNA damage was53
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Figure 2. DBC1 Deficiency Leads to Less
p53 Protein
(A and B) p53 protein levels decreased in Dbc1/
mouse embryonic fibroblast (MEF) cells. Dbc1+/+
and Dbc1/ MEFs were irradiated with 10 Gy IR
and then harvested 1 hr later (A) or at different time
points (B). Cell lysates from Dbc1+/+ and Dbc1/
cells were blotted with indicated antibodies. LE,
long exposure; SE, short exposure.
(C) Depletion of DBC1 didn’t affect p53 mRNA
levels. mRNA levels were examined inDbc1+/+ and
Dbc1/ MEF cells.
(D) Knockdown of DBC1 decreased p53 protein
levels in normal human fibroblast cells. WI38 and
IMR90 cells were transfectedwith control siRNA or
DBC1 siRNA. At 48 hr later, cells were harvested,
and p53 levels were analyzed by western blot.
, intestine, and lung tissues were removed from Dbc1+/+ and Dbc1/
nalyzed by western blots.
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Figure 3. DBC1 Regulates p53 Stability
(A) p53 protein was less stable in Dbc1/ cells.
Dbc1+/+ and Dbc1/ MEF cells were treated with
cycloheximide (CHX, 0.1 mg/ml) and harvested at
the indicated time. Cell lysates were then blotted
with DBC1, p53, and actin antibodies.
(B) Quantification of p53 half -life results shown in
Figure 3A by Image J software.
(C) DBC1 regulates p53 levels in a proteasome-
dependent manner. Dbc1+/+ and Dbc1/ MEF
cells were treated with DMSO or MG132, and 4 hr
later, cells were harvested and blotted with indi-
cated antibodies.
(D) Ubiquitination of p53 was enhanced inDbc1/
MEF cells. Dbc1+/+ and Dbc1/ MEF cells were
treated DMSO or MG132; 4 hr later, p53 was
immunoprecipitated, and p53 ubiquitination was
examined.
(E) Ubiquitination of p53 was enhanced inDbc1/
MEF cells. Dbc1+/+ and Dbc1/ MEF cells were
transfected with constructs encoding His-Ub;
48 hr later, both cells were treated with DMSO or
MG132 for 4 hr. Then cells were lysed by 6M
Guanidine-HCl, and p53 ubiquitination was
examined by Ni-NTA Agarose bead pull down and
western blots.compromised (Figures 2A, 2B, and S2A). To test whether deple-
tion of DBC1 affect p53 mRNA level, we performed RT-PCR
assay. We did not detect any significant difference of p53
mRNA level between WT and KO cells (Figure 2C). To further
confirm this result in human cells, we knocked down DBC1 in hu-
man primary cells and found that p53 levels also decreased
when DBC1 was depleted (Figure 2D). However, knockdown of
DBC1 in cancer cell lines generated variable results, and some
cell lines showed decreased p53 levels upon DBC1 depletion
(e.g., A549; Figure S2B) while some did not (e.g., U2OS; Fig-
ure S2C). This is probably due to complicated genetic back-
ground in different cancer cell lines. We also tested p53 levels
in vivo using Dbc1 KOmice and found less p53 protein in the tis-
sues of Dbc1/ mice (Figure 2E). These results suggest that
DBC1 regulates p53 levels in vitro and in vivo.
DBC1 Prevents p53 Degradation from Proteasome
To determine whether the half-life of p53 protein was affected
by DBC1, we treated cells with cycloheximide and found
that p53 was degraded much faster in Dbc1 KO cells (Figures
3A and 3B). These results suggest that DBC1 regulates p53
stability. To explore the mechanism of stabilization of p53 by
DBC1, we treated Dbc1+/+ and Dbc1/ cells with MG132.1326 Cell Reports 10, 1324–1334, March 3, 2015 ª2015 The AuthorsThere was no significant difference in
p53 level after MG132 treatment in
both cells (Figure 3C), suggesting that
DBC1 regulates p53 in a proteasome-
dependent manner. We further found
that ubiquitination signals from p53
immunoprecipitates were enhanced in
the absence of DBC1 (Figure 3D). To
exclude the possibility that increasedubiquitination signals are caused by ubiquitination of p53
associated proteins rather than p53 itself, we transfected
His-ub into cells and examined p53 ubiquitination under dena-
tured conditions. This experiment further confirmed increased
ubiquitination of p53 in Dbc1 KO cells (Figure 3E).
DBC1 Competes with MDM2 in p53 Binding
We next studied how DBC1 regulated p53 stability and ubiquiti-
nation. DBC1 was reported to promote acetylation of p53
through inhibiting SIRT1 (Kim et al., 2008; Zhao et al., 2008). If
DBC1 regulates p53 level through SIRT1, we would expect
that inhibiting SIRT1 would rescue p53 loss in Dbc1/ cells.
To test this hypothesis, we knocked down SIRT1 in Dbc1+/+
and Dbc1/ cells and found that depletion of SIRT1 did not
result in increased p53 protein level (Figures 4A and S3A).
Instead, SIRT1 downregulation resulted in slightly decreased
p53 levels. This result suggests that DBC1 stabilizes p53 in an
SIRT1-independent manner.
To study how DBC1 regulates p53, we next examined whether
DBC1 itself interacts with p53. We found that DBC1 coimmuno-
precipitated with p53 and vice versa (Figures 4B and 4C). We
failed to detect an interaction between DBC1 and MDM2 (Fig-
ure 4C). To test whether the interaction between DBC1 and p53
is direct, we purified p53 and DBC1 protein and performed an
in vitro binding assay. As shown in Figure 4D, p53 could directly
pull down DBC1 under cell-free conditions, suggesting a direct
interaction between DBC1 and p53. Next we mapped the
DBC1-p53 interaction with a series of p53 deletion mutants and
found that DBC1 bound to N terminus of p53 (AA1-75) and DNA
binding domain (DBD, AA76-320) (Figures 4E and 4F). Interest-
ingly, previous studies showed that MDM2 bound to the same
region of p53 (Coutts et al., 2009). We also mapped the DBC1
interaction region with p53 and found that N terminus of DBC1
protein was responsible for the interaction with p53 (Figure 4G),
not the leucine zipper domain, which mediated the DBC1 interac-
tion with SIRT1 (Kim et al., 2008). These results led us to hypoth-
esize that DBC1 stabilizes p53 by competing with MDM2 for p53
binding. We carried out an in vitro competition assay and found
that increased doses of DBC1 protein were able to compete off
MDM2 in p53 binding (Figure 4H). DBC1 competed with MDM2
for binding to both p53 N terminus and DBD domain (Figures
S3B and S3C). We also found enhanced MDM2-p53 interaction
in cells in the absence of DBC1 (Figure 4I). Furthermore, treating
cells with theMDM2 inhibitor Nutlin or depletingMDM2by shRNA
could reverse the reduction of p53 protein in DBC1-depleted
cells (Figures 4J and 4K). These results suggest that DBC1 regu-
lates p53 by affecting the MDM2-p53 interaction. This function of
DBC1 is independent of its role in SIRT1 regulation.
Depletion of DBC1 Promotes Cell Proliferation and Cell
Transformation and Favors Multinucleation
It is reported that depletion of p53 induces multinucleated cells
(Armit et al., 2002). We also noticed binucleated cells in DBC1
KO cells (Figures S4A–S4C). To further explore the physiological
function of the DBC1-p53 interaction, we utilized cell growth
assay. We found that deletion of Dbc1 promoted cell prolifera-
tion (Figure 5A, 5B, and S4D). To test whether SIRT1 or p53
involved in DBC1 regulated cell proliferation, we reintroduced
full-length DBC1 and deletion mutants of DBC1 into Dbc1 KO
cells. Reconstitution of full-length DBC1 and DBC1DLZ trun-
cation reversed the increase of cell proliferation, but not
DBC1D1-230 truncation (Figures 5C and 5D). These results sug-
gest that the p53 binding region of DBC1, rather than the SIRT1
binding region, is important for suppression of cell proliferation.
Depletion of p53 causes spontaneous transformation (Hermann-
sta¨dter et al., 2009; Lehnertz et al., 2011). To evaluate whether
Dbc1-deficiency affects cell transformation, we performed col-
ony formation assays. Loss of Dbc1 dramatically increased col-
ony number (Figures 5E and S4E). Reconstitution of full-length
DBC1 and DBC1DLZ, but not DBC1D1-230, blocked cell trans-
formation (Figures 5F and S4F). These results indicate that DBC1
inhibits cell proliferation and transformation and maintains
genome stability through the p53 interaction region.
DBC1 Suppresses Tumorigenesis through p53,
Independent of SIRT1 In Vivo
Because DBC1 suppresses SIRT1 activity, we further tested
whether DBC1 suppresses tumorigenesis through its regulation
of SIRT1 in vivo by crossing Sirt1/ mice and Dbc1/ mice.
We had few Dbc1/;Sirt1/ mice because of breeding diffi-
culties. However, we found that Dbc1/;Sirt1+/ mice showedCesimilar disease-free survival rate and tumor incidence as
Dbc1/;Sirt1+/+ (Figures 6A–6C; Table S3). These results,
together with our in vitro cell transformation results, suggest
that spontaneous tumor development in Dbc1/ is unlikely
through SIRT1. We also generated Dbc1 3 Trp53 double-KO
mice. Trp53/ mice showed low survival rate and high fre-
quency of tumorigenesis, and loss of Dbc1 did not further affect
tumor incidence and mouse survival in Trp53/ background
(Figures 6D and 6E; Table S4). These results suggested that
DBC1 inhibited tumorigenesis mainly through p53 but not
SIRT1 in vivo.
Stabilization of p53 Mutant by DBC1
The reported role of DBC1 in human cancer has been confusing.
DBC1 is found to be downregulated or overexpressed and acts
as a good or bad prognosis marker in human cancers, some-
times in the same type of cancer (Hamaguchi et al., 2002; Kim
et al., 2009 ; Cha et al., 2009; Hiraike et al., 2010; Di Marcotullio
et al., 2011; Noguchi et al., 2014; Bae et al., 2014; Zhang et al.,
2014). To understand the discrepancy, we tested whether
DBC1 affects mutant p53 function. MDA-MB-231 cells were re-
ported to harbor a p53 R280K mutation (Olivier et al., 2002).
Immunoprecipitation assay showed that DBC1 still interacted
with mutant p53 (Figure 7A); mutant p53 levels were also
decreased with loss of DBC1 (Figure 7B), and MDM2 protein
levels were comparable to those in cell lines with WT p53 (Fig-
ure S5). To study whether DBC1 affects mutant p53 stability,
we carried out ubiquitination assay. Similar toWT p53, increased
ubiquitination of mutant p53 was observed after depletion of
DBC1 (Figure 7C). To explore whether DBC1 affects mutant
p53 function, we performed cell proliferation assay and cell
viability assays. Loss of DBC1 in cell lines with mutant p53 sup-
pressed tumor cell proliferation (Figure 7D) and impaired cell
viability under stress (Figures 7E and 7F). These phenotypes
were opposite to what we obtained using cells with WT p53.
These results suggest that DBC1 also stabilizes mutant p53
and promotes its function, and DBC1 could have tumor suppres-
sion or tumor promoting activity depending on genetic back-
ground of p53.
DISCUSSION
Because of the crucial role of p53 in inhibiting cancer, it has
been intensively studied, including the mechanism of its stabili-
zation and activation. p53 stability is predominantly regulated in
a MDM2-dependent manner. The posttranslational modification
of p53, such as phosphorylation, acetylation, methylation, and
deubiquination, affects the interaction between p53 and
MDM2 and thus regulates p53 protein stability (Lavin and Gu-
even, 2006). p53 consists of several different domain: transacti-
vation domain, DNA-binding domain, tetramerization domain,
and C-terminal regulatory domain (Bode and Dong, 2004).
Some proteins compete with MDM2 binding to p53 transactiva-
tion domain and DBD domain and thereby prevent p53 from
ubiquitination. These proteins include Ing1b (Leung et al.,
2002) and DBC1 identified in the current study. DBC1 binds to
the p53 N terminus and DBD domain (Figures 4E and 4F).
MDM2, the E3 ligase of p53 protein, also binds to these samell Reports 10, 1324–1334, March 3, 2015 ª2015 The Authors 1327
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Figure 4. DBC1 Directly Binds p53 and Competes with MDM2
(A) DBC1 stabilized p53 in an SIRT1-independent manner. Dbc1+/+ and Dbc1/ MEFs were infected with lentivirus encoding control shRNA or SIRT1 shRNA.
Cells were left untreated or treated with IR (10 Gy), and p53 levels were examined.
(B and C) p53 interacted with DBC1. MEFs were lysed, and the p53-DBC1 interaction was examined by coimmunoprecipitation (Co-IP).
(legend continued on next page)
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regions (Coutts et al., 2009), suggesting the potential competi-
tion between DBC1 and MDM2, which is confirmed by the
in vitro competition assay (Figures 4H, S3B, and S3C).
p53 is the guardian of genome, and Trp53 KO mice have high
tumor incidence, with lymphomas accounting for up to 70% of
the tumors, while the remaining tumors are sarcomas (Jacks
et al., 1994). The tumor spectrum of Dbc1/ mice is different
from that of Trp53 KO mice, but shares similarity with that of
Trp53+/ mice. Like Dbc1/ mice, lymphomas, liver tumors,
lung tumors were developed in Trp53+/ mice. It is possible
that loss of DBC1 caused partial loss of p53 protein in Dbc1/
mice, similar to Trp53+/ mice (Jacks et al., 1994). It is also
possible that p53 is not the only protein to interact with DBC1;
other binding partners may too affect the tumor incidence and
spectrum. Similar differences in tumor spectrum have also
been observed in other established p53 regulators, such as
p19ARF. ARF/ mice have lower incidence of lymphomas
(25%) and primarily have poorly differentiated sarcomas (50%),
with carcinomas and gliomas appearing in other mice (Kamijo
et al., 1997, 1999).
The function of DBC1 in human cancer has been controversial.
It has been suggested to promote or suppress cancer cell
growth in different studies. p53 status might be the cause of
this complexity. The TP53 gene is the most commonly mutated
gene in different types of cancer (Kandoth et al., 2013). Mutant
p53 gains new functions and promotes cancer cell survival, pro-
liferation, andmigration (Muller and Vousden, 2014). In our study,
we found that DBC1 suppressed cell proliferation and tumori-
genesis in WT p53 background in vitro and in vivo. Interestingly,
DBC1 also stabilized p53 R280K mutant in cancer cell and
enhanced cell proliferation and cell viability (Figures 7D–7F).
These results may help shed light on the puzzle of conflicting
DBC1 function in tumors. In the tumor development process,
cancer cells accumulate mutations, such as p53, and these mu-
tants acquire new functions to help tumor progression. A tumor
suppression signaling pathway, such as the DBC1-p53 pathway,
is thus hijacked, to promote tumor development. Therefore,
DBC1 could be a double edged sword through its role in regu-
lating p53.
Taken together, our studies establish for the first time that
DBC1 is a tumor suppressor, identify a SIRT1 independent
function of DBC1, and reveal a new regulatory mechanism of(D) DBC1 directly interacts with p53. Purified His-DBC1 protein was incubated with
were blotted with the indicated antibodies.
(E) Schematic diagram of p53 deletion constructs.
(F) The N terminus and DBD domain of p53 protein interacts with DBC1. GST p
GST-p53 deletion fusion proteins. The samples were blotted with anti-DBC1 and
(G)Mapping domains of DBC1 that interact with p53. DBC1 deletion constructs we
for 3 hr, and the DBC1-p53 interaction was examined by Co-IP.
(H) DBC1 andMDM2 competed for binding p53. A constant amount of MDM2 (1 m
tested for binding to GST-p53, and bound proteins were detected by MDM2 and
(I) Increased p53-MDM2 interaction in the absence of DBC1. Dbc1+/+ and Dbc1
harvested after an extra hour. The MDM2-p53 interaction was then examined.
(J) MDM2 inhibitor, Nutlin (10 mM) inhibited p53 degradation caused by loss of DB
p53 levels were examined.
(K) Knockdown of MDM2 inhibited p53 decrease caused by loss of DBC1. IMR90
then examined.
See also Figure S3.
Cep53. These studies provide important insights into cancer
etiology.
EXPERIMENTAL PROCEDURES
Animal Studies
All mice in this study were housed in the Mayo Clinic animal breeding facility.
All experimental protocols were approved by the Institutional Animal Care and
Use Committee at Mayo Clinic, and all studies were performed according to
the methods approved in the protocol A19812. Mice were maintained in a
12-hr light/dark cycle, and fed ad libitum normal food. Dbc1/ mice were
generated as described in (Escande et al., 2010). Dbc1+/ mice crossed with
Trp53+/mice to breedDbc13 Trp53 double-KOmice.Dbc1+/mice crossed
with Sirt1+/ mice to breed Dbc1 3 Sirt1 double-KO mice.
Cell Culture, Plasmids, Antibodies and Transfection Reagents
Dbc1+/+ and Dbc1/ MEF cells were cultured in DMEM supplemented with
15% fetal bovine serum (FBS). WI38 and IMR90 cells were cultured in Eagle’s
minimum essential medium (EMEM) supplemented with 10% FBS. All of these
cell lines were kept in a humidified 37C 5% CO2/5% O2 incubator. MDA-MB-
231 cells were cultured in L-15 medium with 10% FBS and were kept in a hu-
midified 37C incubator without CO2.
DBC1-His plasmid and DBC1-HA deletion constructs were described in Kim
et al. (2008). p53 GST deletions were kindly provided by Dr. Sengupta (De
et al., 2012). DBC1 antibodywas described in (Kim et al., 2008). p53 antibodies
(DO-1 and R19) were purchased from Santa Cruz, and p53 antibody (1C12)
was purchased from Cell Signaling Technology. p21 antibody (C-19) and ubiq-
uitin antibody (P4D1) were purchased from Santa Cruz. BrdU antibody was
purchased from BD Bioscience. MDM2 antibody were purchase from
Calbiochem.
Lipofectamine 2000 and 3000 from Invitrogen were used for transfection.
RNA Interference
DBC1 shRNA sh1 (target sequence CCCATCTGTGACTTCCTAGAA), sh2
(target sequence CGGGTCTTCACTGGTATTGTT), and SIRT1 shRNA (target
sequence GCCATGAAGTATGACAAAGAT) were purchased from Sigma.
Lentivirus were made according to manufacturer’s protocol. DBC1 SiRNA
(50-CAGCUUGCAUGACUACUUUUU-30) was purchased from Dharmacon.
Western and Immunoprecipitation Assay
Cells were lysed with 0.5% NP40, 150 mM NaCl, 50 mM Tris, and 1 mM EDTA
(NETN) buffer (20-mM Tris-HCl [pH 8.0], 100-mM NaCl, 1-mM EDTA, 0.5%
Nonidet P-40 with 50-mM b-glycerophosphate, 10-mM NaF, and 1-mg/ml
each of pepstatin A and aprotinin). After centrifugation, the supernatant was
removed and incubated with antibody and protein A or protein G Sepharose
beads (Amersham Biosciences) for 2 hr or overnight at 4C. The samples
were separated by SDS-PAGE following three washes with NETN buffer.
Western blots were carried out following standard procedures.GST or GST-p53 coupled to GSH-Sepharose. Proteins retained on Sepharose
ull-down assays were carried out with total cell extracts from MEF cells and
p53 antibodies. GST-fusion proteins were stained with Coomassie blue.
re transfected into DBC1/ cells. At 24 hr later, cells were treated withMG132
g/ml) and increasing amounts of DBC1 (0, 23, 103 relative ratio toMDM2) were
DBC1 antibodies.
/ MEFs were treated DMSO or MG132; 3 hr later, cells were irradiated and
C1. Dbc1+/+ andDbc1/MEFs were treated with or without Nutlin for 8 hr, and
cells were infected with lentivirus encoding indicated shRNA. p53 levels were
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Figure 5. Depletion of DBC1 Promotes Cell
Growth and Colony Formation
(A and B) Depletion of DBC1 promoted cell
growth. Dbc1+/+ and Dbc1/ MEFs were stained
with BrdU antibody and DAPI (A). Quantification of
BrdU-positive cells in Dbc1+/+ and Dbc1/ MEFs
(B). The data presented are mean ± SEM for three
independent experiments. **p < 0.01.
(C and D). The N terminus of DBC1 is responsible
for inhibition of cell proliferation. (C) Dbc1/ MEF
cells were transfected indicated DBC1 trunca-
tions, and 2 days later, cells were stained with
BrdU antibody. (D) Quantification of BrdU-positive
cells in (C). The data presented are mean ± SEM
for three independent experiments. **p < 0.01.
(Lower) The expression of different DBC1 deletion
mutants.
(E) Depletion of DBC1 promoted cell trans-
formation. Dbc1+/+ and Dbc1/ MEFs were
plated into six-well plates, and 2 weeks later,
colony formation was examined by staining cells
with Giemsa. The data presented are mean ± SEM
for three independent experiments. **p < 0.01.
(F) DBC1 N terminus is responsible for inhibition of
cell transformation. Dbc1/ MEFs reconstituted
with DBC1 truncations as (D) were examined
for colony formation. The data presented are
mean ± SEM for three independent experiments.
**p < 0.01; N.S., not significant.
See also Figure S4.GST Pulldown Assay
GST and p53 deletion GST fusion proteins were purified in a standard way
and incubated with cell lysates. After three washes, the bound proteins
were separated with SDS-PAGE and blotted with indicated antibodies.
His-DBC1 protein was purified from 293T cells transfected with His-DBC1
plasmids by Ni-NTA Agarose. For in vitro binding assay, GST fusion proteins
were incubated with His-DBC1, which was purified from transected
293Tcells. After washes, the complex were separated by SDS-PAGE and
blotted with indicated antibodies.
p53 Ubiquitination Assay
Cells were treated with 10-mM MG132 for 4 hr, and then cells were lysed with
NETN buffer and immunoprecipitated with polyclonal p53 antibody. The im-
munocomplexes were analyzed by western blot.
In Vitro Competition Assay
MDM2-His protein was purchase from Abcam. GST-p53 and p53
deletion fusion proteins were purified from E. coli BL-21 (DE3) (Promega).1330 Cell Reports 10, 1324–1334, March 3, 2015 ª2015 The AuthorsProtein amount was quantified by BCA kit
(Promega); 1-mg/ml MDM2 and 1-mg/ml
GST-p53 protein and increasing amounts of
DBC1 (0, 23, 10 times; relative ratio to MDM2)
were incubated in binding buffer (25-mM Tris
[pH 7.8], 200-mM NaCl, 1-mM EDTA, 1-mM
DTT, 10% glycerol, 0.2% Nonidet P-40, fresh
1-mM phenylmethanesulfonyl fluoride [PMSF])
for 6 hr at 4C. After washing, the bound pro-
teins were eluted with SDS sample buffer and
were separated by SDS-PAGE.
Cell Proliferation Assay
Cells were seeded in 96-well plates, and then for-
mazan production was determined by the CellTiter96 AQueous Non-Radioactive Cell Proliferation Assay kit (Promega). Briefly,
20 ml of MTS were added to each well 3 hr later. The absorbance at 490 nm
was measured with a microplate reader.
BrdU Incorporation Assay
BrdU labeling assay was carried out as described in Chen et al. (2010). Cells
were kept in medium containing 10- mM BrdU (Calbiochem) for 30 min and
then fixed in 4%paraformaldehyde. Cells were permeabilized with 0.5% Triton
X-100 (Sigma), and DNA was denatured in 2-M HCl and then blocked with 1%
goat serum in PBS. Alexa-488-labeled anti-BrdU (Invitrogen) was added. Then
cells were stained with 4,6-diamidino-2-phenylindole (DAPI) to show the
nuclei.
RT-PCR
Total RNAwas extracted with PARIS kit (Applied Biosystems) and was reverse
transcribed with the Superscript First-Strand Synthesis System for RT-PCR
(Invitrogen). Primers for mouse GAPDH and mouse p53 were described in
Heyer et al. (2000).
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Figure 6. DBC1 Inhibits Tumorigenesis through p53 but not Sirt1 In Vivo
(A) Kaplan-Meier disease-free survival curves of Dbc1/Sirt1+/+ (n = 62) and Dbc1/Sirt1+/ (n = 103) mice for 24 months. p = 0.3581.
(B) Tumor incidence in Dbc1/Sirt1+/+ (n = 59) and Dbc1/Sirt1+/ (n = 39) mice.
(C) Representative images of H&E staining of tumors from Dbc1/ Sirt1+/ mice.
(D) Kaplan-Meier disease-free survival curves of Dbc1/Trp53+/+ (n = 62), Dbc1+/+Trp53/ (n = 53) and Dbc1/Trp53/ mice (n = 27) for 24 months,
p < 0.0001.
(E) Tumor incidence in Dbc1/Trp53+/+ (n = 59), Dbc1+/+Trp53/ (n = 8), and Dbc1/Trp53/ (n = 8) mice.
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Figure 7. DBC1 Stabilizes Mutant p53
(A) DBC1 interacted with mutant p53. Co-IP of DBC1 and p53 was examined in MDA-MB-231 cells.
(B) DBC1 downregulation resulted in lower mutant p53 protein. DBC1 was depleted in MDA-MB-231 cells; p53 levels were examined.
(C) Ubiquitination of p53 was enhanced in DBC1-depleted cells. DBC1 was knocked down in MDA-MB-231; p53 ubiquitination was examined by IP and western
blot.
(D) Depletion of DBC1 inhibited MDA-MB-231 cell proliferation. DBC1 was knocked down in MDA-MB-231 cells, and cell proliferation was assessed by 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, Inner Salt (MTS) assay at the indicated time. The data presented are mean
± SEM for three independent experiments. **p < 0.01.
(E and F) Depletion of DBC1 inhibited MDA-MB-231 cell viability under stress. DBC1 was knocked down in MDA-MB-231 cells. Cells were treated with serum
starvation (E) or Paclitaxel (F), and 72 hr later, the cell number was counted. The data presented are mean ± SEM for three independent experiments. *p < 0.05,
**p < 0.01.
See also Figure S5.Immunofluorescent Staining
Cells were seeded on coverslips and then fixed with 4% paraformaldehyde
on ice, washed with PBS, and permeabilized for 10 min with 0.1% Triton
X-100. Cells were blocked with 5% goat serum and then incubated with1332 Cell Reports 10, 1324–1334, March 3, 2015 ª2015 The Authorsalpha tubulin for 1 hr at room temperature. After washing with PBS, Alexa-
488-conjugated anti-mouse antibody (Jackson ImmunoResearch) was
added and incubated for 30 min at room temperature. At last cells were
counterstained with DAPI.
Histology
Tissues were removed and then fixed in formalin. Paraffin tissue sections were
stained with hematoxylin and eosin (H&E) to evaluate histology following the
standard protocol.
Statistical Analysis
For survival curve, log-rank test was used for statistical analysis. For the
rest, comparisons were carried out with a two-tailed unpaired Student’s
t test (*p < 0.05, **p < 0.01). Results are presented as mean ± SEM.
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